Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis

Launched by FIFTH AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Jul 27, 2021

Keywords

ClinConnect Summary

This clinical trial is exploring the effectiveness of two Chinese herbal treatments—Dachaihu Decoction Compound (DDC) and Rhubarb Single Medicine (RSM)—for helping people with acute pancreatitis. Acute pancreatitis is a sudden inflammation of the pancreas, which can cause severe abdominal pain and other symptoms. The goal of the study is to see if these herbal remedies can improve recovery by supporting digestive health and reducing inflammation in the pancreas.

To participate in the trial, individuals need to be between 18 and 65 years old and diagnosed with acute pancreatitis within the last 48 hours. Participants must agree to join the study by signing an informed consent form. However, certain people won't be eligible, such as pregnant or breastfeeding women, those with serious medical conditions affecting vital organs, or anyone with a history of severe allergies or certain illnesses. If you qualify and choose to participate, you can expect to receive either of the herbal treatments and be monitored by healthcare professionals throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age from 18 to 65 years old
• • Meet the diagnostic criteria of western medicine for acute pancreatitis, within 48 hours of onset
• • Consent of the subjects, who sign the informed consent form
• Exclusion Criteria:
• • Women who are pregnant or breastfeeding
• • Acute abdomen such as organic intestinal obstruction, gastrointestinal perforation, purulent cholangitis, etc.
• • Patients with a history of severe heart, liver, kidney and other important organ diseases
• • Patients with mental illness and malignant tumors
• • People who have allergies, or are allergic to a certain drug ingredient